LGVN: Longeveron Inc. Stock

by  •  • Comments Off on LGVN: Longeveron Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 9.21
Enterprise Value ($M) 7.27
Book Value ($M) 3.04
Book Value / Share 0.42
Price / Book 3.03
NCAV ($M) -2.90
NCAV / Share -0.40
Price / NCAV -3.18

Profitability (mra)
Return on Invested Capital (ROIC) -4.22
Return on Assets (ROA) -0.95
Return on Equity (ROE) -1.28

Liquidity (mrq)
Quick Ratio 0.71
Current Ratio 0.71

Balance Sheet (mrq) ($M)
Current Assets 3.76
Assets 9.70
Liabilities 6.66
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.71
Operating Income -21.01
Net Income -21.41

Cash Flow Statement (mra) ($M)
Cash From Operations -19.00
Cash from Investing 8.19
Cash from Financing 5.26

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-17 13G Intracoastal Capital, Llc 4.99
04-15 13D/A Hare Joshua 25.70 -86.42
02-14 13G Armistice Capital, Llc 7.31

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-03-11 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRAN
2024-02-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT T
2023-08-11 10-Q Form 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-20 50,840 302,061 16.83
2024-05-17 44,505 20,305 219.18
2024-05-16 84,825 42,121 201.38
2024-05-15 84,460 498,334 16.95

(click for more detail)

Similar Companies
LABP – Landos Biopharma, Inc. LEXX – Lexaria Bioscience Corp.
LFVN – LifeVantage Corporation LIFE – aTyr Pharma, Inc.
LIPO – Lipella Pharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io